J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi

Johnson & Johnson’s Tremfya is relatively new to the psoriatic arthritis race, where multiple players are vying for market share. Facing a new high-profile in-class rival from AbbVie, the New Jersey pharma is building its case against older agents.